Intervene Immune

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Intervene Immune sits in the upper half of US sponsors by registered trial count (#7,390 of 15,751 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Intervene Immune: 1 sponsored US clinical trial, 1 recruiting.

Intervene Immune sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immunosenescence, with 1 trials.

Mid-pack sponsor footprint

Intervene Immune is in the upper half of sponsors by trial count (#7,390 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

What is open in the Intervene Immune pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Immunosenescence (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Nationwide sponsors with similar pipelines

Cross-sponsor peers matched on registered trial volume and open-enrollment share, not the same therapeutic-area sidebar.

Similar trial volume (± open share)

Similar open-enrollment share (± trial volume)

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.